Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of March 2021, with a specific reporting date of March 11, 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume (Shares) | Exchange |
|---|---|---|---|---|
| 2021-03-09 | Ordinary Shares (25p each) | £12.671 | 198 (Aggregated across 12 individuals) | London Stock Exchange (XLON) |
Note: The total volume is derived from 11 individuals acquiring 20 shares each and 1 individual (PCA of Ms S Jackson) acquiring 18 shares.
Material Changes
This filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It is a routine disclosure of employee share plan acquisitions.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed as acquisitions under the Company's Share Reward Plan, consisting of partnership shares and matching shares.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of Ordinary Shares under the Share Reward Plan, not open market sales or purchases.
- Participants: Transactions involved 12 individuals, including the CEO (Ms E Walmsley), President of Global Vaccines (Mr R Connor), and other senior executives.
- Pricing Consistency: All shares were acquired at a uniform price of £12.671 per share on March 9, 2021.
- Volume Scale: The total number of shares acquired by these insiders in this specific batch was minimal (198 shares total), representing standard plan participation rather than significant capital movement.